New Research Report on Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 by MarketResearchReports
Albany, NY, February 24, 2013 --(PR.com
)-- Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose.
GBI Research, the leading business intelligence provider, has released its latest research, Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose, which provides essential insights into seasonal influenza vaccines sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2018. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape.
GBI Research expects the market to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the 20112018 period from $2.9 billion in 2011 to $3.8 billion by 2018, driven by growing awareness, increasing vaccination coverage and rising government support for immunization against seasonal influenza. On the other hand, limited production capacity, high investment and strict regulations may act as barriers to entry.
To Buy The Copy Of This Report Visit: http://www.marketresearchreports.biz/analysis-details/seasonal-influenza-vaccines-market-in-top-seven-countries-to-2018-next-generation-quadrivalent-vaccines-to-dominate-the-market-by-offering-broader-protection-via-single-dose
The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germany's market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.
Data and analysis on the seasonal influenza vaccine market in the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan
Market forecasts for seasonal influenza vaccines until 2018
Market data on geographical landscape in terms of country, vaccination coverage, public and private contribution to the total number of doses, vaccine price and market size
Key drivers and restraints that have had a significant impact on the market
Regulatory landscape, including the approval process and an overview of the regulatory authorities in the top seven countries
Competitive landscape of the seasonal influenza vaccine market in the top seven countries including top companies profiles, namely Sanofi, Johnson & Johnson, GlaxoSmithKline Biologicals, Novartis Vaccines and AstraZeneca
Key M&A activities and licensing agreements that have taken place between 2009 and mid-2012
To Read The Complete Report with TOC Kindly Visit: http://www.marketresearchreports.biz/analysis/145794
Reasons to buy
Build effective strategies to launch pipeline products by identifying potential geographies
Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps
Develop key strategic initiatives by studying top competitors key strategies
Develop market-entry and market-expansion strategies by identifying the markets poised for strong growth
Reinforce R&D pipelines by identifying new target mechanisms able to produce safer and more efficacious first-in-class vaccines
For More Information Contact:
90 State Street, Suite 700
Albany, NY 12207